Hotmeo

Hotspot Therapeutics is a biotechnology company pioneering a new class of small molecule medicines that target naturally occurring regulatory sites on proteins known as "hotspots." By utilizing its proprietary SmartAllostery platform, the company identifies these allosteric pockets to develop highly selective inhibitors for proteins that were previously considered undruggable. The company's lead program, HST-1011, is an orally bioavailable CBL-B inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Hotspot's pipeline also includes programs targeting E3 ligases and kinases for applications in oncology and autoimmune disorders. The company is backed by leading life science investors and has established strategic collaborations to expand the reach of its allosteric drug discovery engine.